Stock listing

BOATS:PEPG PepGen Inc. Stock

US listing (BOATS) of PepGen Inc. · home listing NASDAQ:PEPG

Follow PepGen Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:PEPG

$3.78 USD -0.05 (-1.3%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:PEPG

Past year -25.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.69 – $3.98 USDNov 20, 2026
Volume
4.43M sharesNov 20, 2026
Market cap
$261.8M USDAt the close on Nov 20, 2026 · price × 69.26M shares outstanding
52-week range
$1.31 – $7.80 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$13.23M USDMedian day 782,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
PepGen Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PEPG · Home$3.78 USD-0.05 (-1.3%)4,429,478$3.86$3.98$3.69$3.83Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PEPG · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.78-0.05-1.3%$3.86$3.98$3.694,429,478
$3.83-0.05-1.3%$4.15$4.21$3.7353,386,571
$3.88-0.31-7.4%$4.09$4.20$3.6155,606,468
$4.19-0.17-3.9%$4.27$4.34$4.1052,606,674
$4.36-0.68-13.5%$5.05$5.05$4.345,890,927
$5.04-0.22-4.2%$5.26$5.35$4.8412,026,554
$5.26+0.65+14.1%$5.40$5.90$5.10516,011,177
$4.61+2.22+92.9%$5.545$6.45$4.42106,515,887
$2.39-0.08-3.2%$2.52$2.52$2.281,376,439
$2.47+0.15+6.5%$2.33$2.52$2.33998,200
$2.32-0.13-5.3%$2.55$2.55$2.22958,800
$2.45-0.01-0.4%$2.53$2.69$2.3751,800,600
$2.46+0.11+4.7%$2.36$2.485$2.36612,500
$2.35-0.01-0.4%$2.39$2.467$2.305565,900
$2.36-0.05-2.1%$2.40$2.405$2.221,129,000
$2.41-0.12-4.7%$2.54$2.62$2.40766,600
$2.53-0.07-2.7%$2.58$2.64$2.485767,800
$2.60+0.11+4.4%$2.49$2.62$2.471,332,000
$2.49-0.03-1.2%$2.51$2.675$2.46906,900
$2.52-0.18-6.7%$2.68$2.80$2.441,161,300
$2.70-0.02-0.7%$2.71$2.83$2.651,041,900
$2.72-0.15-5.2%$2.89$2.99$2.721,173,900
$2.87+0.17+6.3%$2.66$2.94$2.622,761,600
$2.70+0.10+3.8%$2.55$2.73$2.4951,083,000
$2.60+0.07+2.8%$2.56$2.69$2.501,199,500
$2.53+0.21+9.1%$2.30$2.60$2.30764,200
$2.32-0.18-7.2%$2.44$2.49$2.26917,300
$2.50+0.01+0.4%$2.48$2.60$2.411,218,300
$2.49-0.13-5.0%$2.61$2.61$2.48315,800
$2.62+0.24+10.1%$2.39$2.65$2.39603,700
$2.38-0.02-0.8%$2.38$2.447$2.28844,600
$2.40+0.09+3.9%$2.31$2.48$2.275642,800
$2.31-0.05-2.1%$2.38$2.385$2.26590,200
$2.36+0.08+3.5%$2.30$2.39$2.255606,400
$2.28+0.07+3.2%$2.24$2.31$2.225744,400
$2.21-0.21-8.7%$2.38$2.425$2.21782,900
$2.42+0.08+3.4%$2.34$2.525$2.342,149,500
$2.34-0.25-9.7%$2.61$2.65$2.322,349,500
$2.590.000.0%$2.55$2.645$2.46740,000
$2.59-0.09-3.4%$2.68$2.72$2.585513,200
$2.68-0.04-1.5%$2.71$2.715$2.63657,400
$2.72-0.26-8.7%$2.95$2.96$2.695715,400
$2.98+0.14+4.9%$2.84$3.03$2.82523,500
$2.84-0.01-0.4%$2.88$2.915$2.80652,400
$2.85-0.12-4.0%$2.97$2.98$2.835580,400
$2.97+0.07+2.4%$2.90$2.99$2.85447,600
$2.90+0.01+0.3%$2.92$2.975$2.85613,200
$2.89-0.08-2.7%$2.93$2.94$2.84567,300
$2.97-0.01-0.3%$2.99$3.10$2.91718,400
$2.98-0.04-1.3%$3.03$3.10$2.95683,000
$3.02-0.13-4.1%$3.13$3.13$3.00972,800
$3.15-0.06-1.9%$3.17$3.48$3.101,153,700
$3.21+0.10+3.2%$3.06$3.24$2.911,929,700
$3.11-0.07-2.2%$3.14$3.195$3.10201,000
$3.180.000.0%$3.18$3.25$3.10514,300
$3.18+0.06+1.9%$3.15$3.30$3.085352,700
$3.12+0.13+4.3%$2.95$3.165$2.91461,800
$2.99-0.09-2.9%$3.04$3.05$2.92365,800
$3.08+0.01+0.3%$3.05$3.13$2.98484,900
$3.07-0.15-4.7%$3.22$3.30$3.07469,900
$3.22-0.205-6.0%$3.41$3.41$3.11952,000
$3.425+0.235+7.4%$3.21$3.57$3.19985,000
$3.19+0.05+1.6%$3.14$3.23$3.04482,700
$3.14+0.105+3.5%$3.09$3.23$3.031671,800
$3.035-0.015-0.5%$3.04$3.18$3.03969,500
Ticker
BOATS:PEPG
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BOATS
Currency
USD

What changed lately

Latest news

All PepGen Inc. news

PepGen Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
14 in the last 12 months · 86 in all · newest Nov 12, 2026 · oldest 2022
Calls
1 call with a replay · 1 with a transcript · latest Mar 6, 2024
Decks
18 decks · latest Nov 10, 2026

Where PepGen Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:PEPG · Home listingNASDAQUnited StatesUSD
BOATS:PEPG · This pageBOATSUnited StatesUSD

Valuation

Price/book 2.5× against a median of 1.2×: 9th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$172.6M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
1.11

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
PepGen Inc. · NASDAQ:PEPGUS$261.8MUS$172.6Mn/an/an/a2.5×n/a0.1×1.11
AgomAb Therapeutics NV · NASDAQ:AGMBUS$268.4M−US$6.88Mn/an/an/a0.9×n/a0.0×1.29
Kyverna Therapeutics, Inc. · NASDAQ:KYTXUS$263.5MUS$117.8Mn/an/an/a2.0×n/a0.2×2.02
Ocugen, Inc. · NASDAQ:OCGNUS$260.6MUS$178.1Mn/a37.3×n/an/an/an/a1.47
Altimmune, Inc. · NASDAQ:ALTUS$258.8MUS$28.73Mn/an/an/a0.6×n/a0.1×1.55
Prelude Therapeutics Incorporated · NASDAQ:PRLDUS$258.6MUS$136.2Mn/a6.3×n/a2.1×−247.1%0.1×1.48
OBI Pharma, Inc. · TPEX:4174US$258.5MUS$243.4Mn/a154×n/a5.7×n/a0.0×n/a
TransThera Sciences (Nanjing). Inc. · HKEX:2617US$257.1MUS$119.4Mn/an/an/a2.0×n/a0.0×n/a
Eikon Therapeutics, Inc. · NASDAQ:EIKNUS$256.8MUS$44.67Mn/an/an/a0.7×n/a0.7×1.91
SAB Biotherapeutics, Inc. · NASDAQ:SABSUS$255.7MUS$156.5Mn/an/an/a1.2×n/a0.0×1.19
Evommune, Inc. · NYSE:EVMNUS$255.5MUS$86.86Mn/an/an/a1.0×n/a0.0×0.96
Median of the othersUS$258.5MUS$118.6M37.3×1.2×−247.1%0.0×1.48

Forecasts

7 strong buy · 1 sell · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
12.13 USD · Analysts' mean
EPS, year to Dec 2026
-1.14 · 3 analysts

Team and board

Officers

OfficerRole
James McarthurPresident and Chief Executive Officer
Noel DonnellyChief Financial Officer
Emiko BryantSenior Vice President, HR and Administration
Hayley ParkerSenior Vice President, Global Regulatory Affairs & Quality
Paul StreckExecutive Vice President, Head of Research & Development
Christopher AbbottExecutive Director, CMC
Hongling HanExecutive Director, Analytical Development and QC
Joseph VittiglioChief Business and Legal Officer
Kasra KasraianChief Technical Officer
Melissa MichaelsExecutive Director, Head of Regulatory Affairs CMC
Sarah VaccaExecutive Director, Clinical Operations

Board

DirectorRole
Christopher AbbottExecutive Director, CMC
Habib Joseph DableNon-Executive Director
Heidi HensonNon-Executive Director
Hongling HanExecutive Director, Analytical Development and QC
Howard MayerNon-Executive Director
Josh ResnickNon-Executive Director
Lisa WymanNon-Executive Director
Melissa MichaelsExecutive Director, Head of Regulatory Affairs CMC
Mitch FinerNon-Executive Director
Sarah VaccaExecutive Director, Clinical Operations

Events

Calls

CallWhenStatus
PepGen (NASDAQ:PEPG) Q4 2023 Earnings CallWed, Mar 06, 2024 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open+92.9%
Q2 2026Aug 6, 2026 · Before open+21.7%
Q1 2026May 7, 2026−4.6%
Q4 2025Mar 4, 2026 · After close−18.6%
Q3 2025Nov 12, 2025 · Before open+10.3%
Q2 2025Aug 7, 2025 · Before open−13.1%
Q1 2025May 8, 2025 · Before open+22.2%
Q4 2024Feb 24, 2025+24.8%
Q3 2024Nov 7, 2024 · Before open−21.7%
Q2 2024Aug 8, 2024 · Before open+1.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · After close−1.2%
Q4 2023Mar 6, 2024 · After close−8.0%
Q3 2023Nov 8, 2023 · Before open−10.4%
Q2 2023Aug 8, 2023 · Before open+2.6%
Q1 2023May 11, 2023 · Before open−2.9%
Q4 2022Mar 23, 2023 · After close−9.8%
Q3 2022Nov 10, 2022 · Before open+12.9%
Q2 2022Aug 12, 2022 · Before open−6.7%
Q1 2022Jun 16, 2022 · Before open+12.7%
Q4 2021Feb 11, 2022

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (November 2026)Technical26 slidesNov 10, 2026
Investor Presentation (August 2026)Investor deck29 slidesAug 6, 2026
Investor Presentation (August 2026)Investor deck29 slidesAugust 2026
Investor Presentation (May 2026)Investor deck27 slidesMay 21, 2026
IDMC 2026 Late-BreakerConference19 slidesMay 2026
Corporate Update (March 2026)Corporate update17 slidesMar 30, 2026
Investor Presentation (March 2026)Investor deck20 slidesMar 4, 2026
OTS Annual Meeting 2025Conference17 slidesOct 22, 2025
Investor Presentation (October 2025)Investor deck21 slidesOct 1, 2025
Technical Presentation (September 2025)Technical18 slidesSeptember 2025
All 18 decks
DeckKindSlidesDate
Investor Presentation (May 2025)Investor deck27 slidesMay 28, 2025
MDF Conference 2025Conference12 slidesMay 2025
Needham Conference 2025Conference33 slidesApril 2025
Technical Presentation (February 2025)Technical24 slidesFeb 24, 2025
Technical Presentation (July 2024)Technical34 slidesJul 30, 2024
Technical Presentation (2024)Technical9 slides2024
Investor Presentation (March 2023)Investor deck63 slidesMar 27, 2023
Corporate Update (September 2022)Corporate update24 slidesSep 28, 2022

Open Decks

Financings

RaiseDate
Public offering of common stock
Update: US$125M · US$5 a share · Leerink Partners +4
Dealers: Leerink Partners (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead), Oppenheimer & Co., H.C. Wainwright & Co.
Use of proceeds: Fund ongoing clinical development of its product candidate, working capital and general corporate purposes
Nov 12, 2026
Public offering of common stock
Closed: US$115M raised · US$3.2 a share · Leerink Partners +1
Dealers: Leerink Partners (co-lead), Stifel (co-lead)
Use of proceeds: Research and clinical development, including the FREEDOM-DM1 and FREEDOM2-DM1 trials, working capital and general corporate purposes
Sep 29, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$12.00 a share on May 5, 2022.

Price
US$12.00 a share
Shares offered
9,000,000 shares of common stock
Offering size
US$108 million
Underwriters' option
Up to 1,350,000 more shares
Underwriters
BofA Securities, SVB Securities, Stifel, Wedbush PacGrow · In the order on the cover
Shares delivered
On or about May 10, 2022

Steps

StepWhen
Draft sent to the SEC in confidenceOct 1, 2021
Filed publiclyApr 15, 2022
Amended 3 timesNewest May 10, 2022
Shares registered with an exchangeMay 3, 2022
Declared effective by the SECMay 5, 2022
Final prospectus, with the priceMay 9, 2022

Open IPO · From the cover of the final prospectus (424B4) filed May 9, 2022

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue000000
Cost of revenue1.40M1.50M1.18M493.0K178.0K110.0K106.0K
Gross profit-1.40M-1.50M-1.18M-493.0K-178.0K-110.0K-106.0K
Research and development71.0M76.5M68.1M54.1M19.0M1.12M620.0K
Selling, general and administrative22.6M21.3M16.6M14.2M8.11M853.0K628.0K
Operating income-93.6M-97.7M-84.8M-68.3M-27.1M-1.88M-1.35M
Depreciation and amortization1.40M1.50M1.20M500.0K200.0K110.0K106.0K
EBITDA-92.2M-96.2M-83.6M-67.8M-26.9M-1.77M-1.25M
Interest expense3.40M172.0K8.00K0
Income before tax-89.6M-90.6M-78.6M-65.4M-27.3M-1.89M-1.35M
Income tax48.9K-617.0K73.0K3.70M0-8.00K
Net income-89.7M-90.0M-78.6M-69.1M-27.3M-1.89M-1.35M
Earnings per share, basic-2.12-2.85-3.30-4.42-30.27-0.08-0.06
Earnings per share, diluted-2.12-2.85-3.30-4.42-30.27

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents60.5M49.4M80.8M181.8M132.9M9.78M3.49M
Short-term investments87.9M70.8M29.6M0
Receivables58.0K4.74M407.0K230.0K
Current assets151.0M123.8M112.7M186.1M140.0M10.3M3.77M
Property, plant and equipment1.90M3.72M4.76M3.33M636.0K323.0K419.0K
Total assets173.9M150.9M143.1M217.4M143.6M10.6M4.19M
Accounts payable822.0K1.75M1.00M1.36M3.24M721.0K141.0K
Current liabilities12.6M16.7M17.5M18.8M10.3M838.0K326.0K
Total debt17.0M18.7M20.1M24.5M
Total liabilities26.5M32.3M34.6M37.8M10.5M868.0K326.0K
Shareholders' equity147.4M118.6M108.4M179.6M-32.1M9.77M3.87M
Shares outstanding68.9M32.6M23.8M23.7M963.6K22.4M22.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-81.6M-82.4M-69.0M-59.3M-22.6M-1.65M-885.0K
Capital spending-264.0K-497.0K-2.60M-3.75M-500.0K-8.00K-29.0K
Free cash flow-81.9M-82.9M-71.6M-63.0M-23.1M-1.66M-914.0K
Cash from investing-15.2M-37.7M-32.0M-3.75M-500.0K-8.00K-29.0K
Cash from financing108.0M88.7M-189.0K112.2M147.7M7.95M2.79M
Share buybacks114.9M
Change in cash11.1M-31.4M-100.9M48.9M124.6M6.29M1.88M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13D/A · Big-stake notice, amendedNov 17, 2026Big-stake noticeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
8-K · Current reportNov 12, 2026Material contractSEC
424B5 · ProspectusNov 12, 2026Offer documentSEC
424B5 · ProspectusNov 10, 2026Offer documentSEC
8-K · Current reportNov 10, 2026ResultsSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportJun 22, 2026Meeting outcomeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveMay 22, 2026Other filingsSEC
8-K · Current reportMay 21, 2026Current reportSEC
CORRESP · Letter to the SECMay 19, 2026Other filingsSEC
S-3 · Registration statementMay 19, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 12, 2026ResultsSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
UPLOAD · Letter from the SECApr 17, 2026Other filingsSEC
DRS · Draft registration statementApr 15, 2026Offer documentSEC
8-K · Current reportMar 30, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeMar 11, 2026Big-stake noticeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
8-K · Current reportMar 4, 2026Current reportSEC
S-8 · Registration statement for employee plansMar 4, 2026Offer documentSEC
10-K · Annual reportMar 4, 2026Annual reportSEC
8-K · Current reportMar 4, 2026ResultsSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 10, 2025Insider tradeSEC
8-K · Current reportDec 8, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 12, 2025ResultsSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 7, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeOct 3, 2025Big-stake noticeSEC
8-K · Current reportOct 1, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 1, 2025Big-stake noticeSEC
4 · Change in ownershipOct 1, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 30, 2025Big-stake noticeSEC
4 · Change in ownershipSep 30, 2025Insider tradeSEC
8-K · Current reportSep 26, 2025Material contractSEC
424B5 · ProspectusSep 25, 2025Offer documentSEC
424B5 · ProspectusSep 24, 2025Offer documentSEC
8-K · Current reportSep 24, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
8-K · Current reportAug 7, 2025ResultsSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
8-K · Current reportJun 6, 2025Meeting outcomeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
8-K · Current reportMay 28, 2025Current reportSEC
4 · Change in ownershipMay 21, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 21, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
8-K · Current reportMay 8, 2025ResultsSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
4 · Change in ownershipApr 22, 2025Insider tradeSEC
4 · Change in ownershipApr 9, 2025Insider tradeSEC
8-K · Current reportMar 31, 2025Management or board changeSEC
4 · Change in ownershipMar 31, 2025Insider tradeSEC
4 · Change in ownershipMar 31, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 31, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 31, 2025Insider tradeSEC
8-K · Current reportMar 28, 2025Management or board changeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
8-K · Current reportMar 4, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 28, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
S-8 · Registration statement for employee plansFeb 24, 2025Offer documentSEC
8-K · Current reportFeb 24, 2025ResultsSEC
10-K · Annual reportFeb 24, 2025Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 7, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 7, 2025Big-stake noticeSEC
8-K · Current reportJan 29, 2025Current reportSEC
8-K · Current reportDec 16, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
8-K · Current reportOct 8, 2024Current reportSEC
8-K · Current reportSep 19, 2024Management or board changeSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 20, 2024Insider tradeSEC
8-K · Current reportAug 20, 2024Current reportSEC
SC 13G · Big-stake noticeAug 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
8-K · Current reportJul 30, 2024Current reportSEC
4 · Change in ownershipJul 26, 2024Insider tradeSEC
4 · Change in ownershipJul 19, 2024Insider tradeSEC
4 · Change in ownershipJul 16, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveJul 9, 2024Other filingsSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
CORRESP · Letter to the SECJul 3, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 2, 2024Other filingsSEC
8-K · Current reportJul 2, 2024Current reportSEC
S-3 · Registration statementJun 28, 2024Offer documentSEC
4 · Change in ownershipJun 26, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
8-K · Current reportJun 20, 2024Meeting outcomeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
8-K · Current reportJun 11, 2024Current reportSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
144 · Notice of proposed saleJun 5, 2024Other filingsSEC
4 · Change in ownershipMay 17, 2024Insider tradeSEC
144 · Notice of proposed saleMay 17, 2024Other filingsSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
DEFA14A · Additional proxy materialMay 1, 2024Meeting noticeSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 16, 2024Meeting noticeSEC
4/A · Change in ownership, amendedApr 9, 2024Insider tradeSEC
SC 13G · Big-stake noticeApr 9, 2024Big-stake noticeSEC
10-K/A · Annual report, amendedMar 29, 2024Annual reportSEC
8-K · Current reportMar 15, 2024Current reportSEC
8-K · Current reportMar 13, 2024Current reportSEC
144 · Notice of proposed saleMar 12, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedMar 11, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansMar 6, 2024Offer documentSEC
10-K · Annual reportMar 6, 2024Annual reportSEC
8-K · Current reportMar 6, 2024ResultsSEC
8-K · Current reportMar 4, 2024Current reportSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
8-K · Current reportFeb 20, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
424B5 · ProspectusFeb 7, 2024Offer documentSEC
8-K · Current reportFeb 7, 2024Material contractSEC
4 · Change in ownershipJan 17, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 17, 2024Insider tradeSEC
8-K · Current reportJan 17, 2024Current reportSEC
8-K · Current reportJan 8, 2024Current reportSEC
8-K · Current reportDec 18, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedDec 11, 2023Big-stake noticeSEC
4 · Change in ownershipDec 5, 2023Insider tradeSEC
8-K · Current reportNov 15, 2023Management or board changeSEC
4 · Change in ownershipNov 14, 2023Insider tradeSEC
3 · Initial statement of ownershipNov 14, 2023Insider tradeSEC
10-Q · Quarterly reportNov 8, 2023Quarterly reportSEC
8-K · Current reportNov 8, 2023ResultsSEC
8-K · Current reportOct 12, 2023Current reportSEC
8-K · Current reportSep 6, 2023Current reportSEC
8-K · Current reportSep 6, 2023Current reportSEC
424B5 · ProspectusAug 8, 2023Offer documentSEC
8-K · Current reportAug 8, 2023Material contractSEC
10-Q · Quarterly reportAug 8, 2023Quarterly reportSEC
8-K · Current reportAug 8, 2023ResultsSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC

This page holds 200 of 311 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from PepGen Inc.’s releases · as of Nov 4, 2026

Common shares
69,261,282
Fully diluted
69,261,282

Fully diluted

LineSharesAs of
Common shares69,261,282Nov 4, 2026

Share count over time

CountShares
Nov 4, 202669,261,282

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Ra Capital Management, L.P.20.1M29.0%US$48.6MSep 30, 2026
Commodore Capital LP4.47M6.5%US$10.8MSep 30, 2026
Viking Global Investors LP3.48M5.0%US$8.43MSep 30, 2026
Laurion Capital Management LP2.75M4.0%US$6.66MSep 30, 2026
Vivo Capital, LLC2.33M3.4%US$5.63MSep 30, 2026
Vanguard2.29M3.3%US$5.54MSep 30, 2026
Marshall Wace, LLP2.05M3.0%US$4.96MSep 30, 2026
Rosalind Advisors, Inc.2M2.9%US$4.84MSep 30, 2026
AWM Investment Company, Inc.1.81M2.6%US$4.37MSep 30, 2026
ADAR1 Capital Management, LLC1.44M2.1%US$3.49MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
BlackRock1.35M1.9%US$3.26MSep 30, 2026
Millennium1.14M1.6%US$2.76MSep 30, 2026
Renaissance Technologies881K1.3%US$2.13MSep 30, 2026
Ikarian Capital, LLC694K1.0%US$1.68MSep 30, 2026
Squadron Capital Management LLC600K0.87%US$1.45MSep 30, 2026
Monimus Capital Management, LP588K0.85%US$1.42MSep 30, 2026
Susquehanna531K0.77%US$1.29MSep 30, 2026
Boothbay Fund Management, LLC500K0.72%US$1.21MSep 30, 2026
Gsa Capital Partners LLP488K0.70%US$1.18MSep 30, 2026
Geode Capital485K0.70%US$1.17MSep 30, 2026
Citadel399K0.58%US$966KSep 30, 2026
Creek Drive Management Group LLC370K0.53%US$895KSep 30, 2026
Jane Street297K0.43%US$718KSep 30, 2026
Driehaus Capital Management LLC280K0.40%US$677KSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.249K0.36%US$603KSep 30, 2026
State Street221K0.32%US$535KSep 30, 2026
Artia Global Partners LP205K0.30%US$497KSep 30, 2026
Qube Research & Technologies Ltd200K0.29%US$483KSep 30, 2026
Dimensional181K0.26%US$438KSep 30, 2026
Brendel Financial Advisors LLC126K0.18%US$306KSep 30, 2026
Palumbo Wealth Management LLC119K0.17%US$288KSep 30, 2026
Squarepoint Ops LLC117K0.17%US$284KSep 30, 2026
Simplex Trading, LLC109K0.16%US$264KSep 30, 2026
Schonfeld Strategic Advisors LLC99,5100.14%US$241KSep 30, 2026
Northern Trust96,6630.14%US$234KSep 30, 2026
XTX Topco Ltd95,9030.14%US$232KSep 30, 2026
RBF Capital, LLC95,0420.14%US$230KSep 30, 2026
Goldman Sachs94,7880.14%US$229KSep 30, 2026
Bridgeway Capital Management, LLC92,2760.13%US$223KSep 30, 2026
Jacobs Levy Equity Management, Inc86,6310.13%US$210KSep 30, 2026
Empowered Funds, LLC84,5760.12%US$205KSep 30, 2026
Axq Capital, LP81,6740.12%US$198KSep 30, 2026
Verdad Advisers, LP59,2800.09%US$143KSep 30, 2026
Quadrature Capital Ltd56,6410.08%US$137KSep 30, 2026
Jump Financial, LLC46,9250.07%US$114KSep 30, 2026
American Century42,6010.06%US$103KSep 30, 2026
Barclays40,6760.06%US$98,437Sep 30, 2026
Rangeley Capital, LLC39,4990.06%US$95,588Sep 30, 2026
Two Sigma37,5780.05%US$90,939Sep 30, 2026
Citigroup Inc35,3410.05%US$85,525Sep 30, 2026

This page holds 50 of 80 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.41M2.0%US$2.54MJun 30, 2026
Vanguard Extended Market Index Fund481K0.69%US$866KJun 30, 2026
iShares Biotechnology ETF449K0.65%US$807KJun 30, 2026
Fidelity Extended Market Index Fund230K0.33%US$345KMay 31, 2026
iShares Micro-Cap ETF141K0.20%US$253KJun 30, 2026
Fidelity Total Market Index Fund86,2490.12%US$129KMay 31, 2026
Ultra-Small Company Market Fund86,0000.12%US$155KJun 30, 2026
Fidelity Series Total Market Index Fund69,1700.10%US$104KMay 31, 2026
Fidelity Nasdaq Composite Index Fund42,6750.06%US$64,013May 31, 2026
Avantis U.S. Small Cap Equity ETF42,6010.06%US$63,902May 31, 2026
All 19 holders
HolderSharesOf the companyValueAs of
Vanguard Balanced Index Fund26,6730.04%US$48,011Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund19,8890.03%US$35,800Jun 30, 2026
1290 VT Micro Cap Portfolio9,5170.01%US$17,131Jun 30, 2026
JNL/DFA U.S. Small Cap Fund5,789<0.01%US$10,420Jun 30, 2026
Invesco Nasdaq Biotechnology ETF3,627<0.01%US$5,441May 31, 2026
iShares Neuroscience and Healthcare ETF3,476<0.01%US$6,118Jul 31, 2026
ProShares Ultra Nasdaq Biotechnology2,541<0.01%US$3,812May 31, 2026
Total Stock Market Index Trust1,319<0.01%US$2,374Jun 30, 2026
Knights of Columbus U.S. ALL CAP INDEX FUND237<0.01%US$417Jul 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Ra Capital Management, L.P.
Director, 10% owner
Buy8,625,000USD 5.00US$43.1MNov 13, 2026
Kasraian Kasra
Officer: Chief Technical Officer
Sale1,233USD 1.41US$1,739May 21, 2026

Big stakes

StakeStakeSharesDateFiling
Ra Capital Management, L.P.30.50%28.7MNov 13, 2026Schedule 13D
Oxford Science Enterprises plc7.20%4.96MSep 30, 2025Schedule 13G
Commodore Capital LP6.50%4.47MMar 31, 2026Schedule 13G
Viking Global Investors LP5.03%3.48MMar 31, 2026Schedule 13G
Janus Henderson Group PLC1.60%522KDec 31, 2024Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Since at least May 5, 2022
Habib Joseph Dable
Other companies: Tyra Biosciences, Inc. (Director · Since at least Apr 16, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Relay Therapeutics, Inc. (Director · Since at least Nov 4, 2025); Day One Biopharmaceuticals Inc (Director · Since at least Jan 17, 2024); Blueprint Medicines Corp (Director · Since at least Jun 23, 2022); Jade Biosciences, Inc. (Director · Jul 10, 2023 – Jun 5, 2024 · Past); Albireo Pharma Inc (Director · Aug 8, 2022 – Mar 2, 2023 · Past); Acceleron Pharma Inc (CEO and President, Director · Jan 4, 2021 – Nov 19, 2021 · Past)
Director · Since at least Sep 20, 2022
Mitchell H Finer
Other companies: Turmeric Acquisition Corp (Director · Oct 15, 2020 – Oct 15, 2020 · Past); Oncorus Inc (Director · Oct 1, 2020 – Jun 23, 2022 · Past); Tcr2 Therapeutics Inc (Director · Feb 13, 2019 – Feb 13, 2019 · Past); Adverum Biotechnologies Inc (Director · May 11, 2016 – Jul 31, 2019 · Past); Bluebird bio Inc (Chief Scientific Officer · Jun 18, 2013 – Jun 1, 2015 · Past)
Director · Since at least Mar 27, 2025
Heidi Henson
Other companies: Perspective Therapeutics, Inc. (Director · Since at least Jun 1, 2023); Lisata Therapeutics, Inc. (Director · Since at least Sep 15, 2022); Pardes Biosciences Inc (Chief Financial Officer · Dec 23, 2021 – Aug 31, 2023 · Past); Kura Oncology, Inc. (Chief Financial Officer · Mar 6, 2015 – Jan 24, 2018 · Past)
Non-Executive Director · Since at least May 5, 2022
Joshua Resnick
Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Cidara Therapeutics Inc (Director · Since at least Jan 3, 2025); Jade Biosciences, Inc. (Director · Jun 5, 2024 – Jun 5, 2024 · Past); Vor Biopharma Inc. (Director · May 23, 2024 – May 22, 2025 · Past)
Director · Since at least Jun 20, 2024
Laurie Keating
Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Jul 6, 2026); Immuneering Corporation (Director · Since at least Jul 29, 2021); Imago Biosciences Inc (Director · Nov 17, 2021 – Jan 11, 2023 · Past); Alnylam Pharmaceuticals, Inc. (EVP, Chief Legal Officer · Jan 11, 2021 – Aug 5, 2021 · Past)
Director · Since at least May 5, 2022
Joseph Vittiglio
Other companies: Bluebird bio Inc (Chief Business & Legal Officer · Since at least May 30, 2025)
Chief Business & Legal Officer · Since at least Dec 8, 2025
Josh Resnick
Other companies: Sionna Therapeutics, Inc. (Director · Since at least Nov 4, 2026)
Non-Executive Director · Since at least Nov 4, 2026
Noel Donnelly
Other companies: Radiopharm Theranostics Limited (Director · Since at least Mar 18, 2026)
Chief Financial Officer · Since at least May 5, 2022
Christopher AbbottExecutive Director, CMC · Since at least Nov 4, 2026
All 29 people
PersonSeat
Christopher AshtonDirector · May 5, 2022 – Jun 20, 2024 · Past
Emiko BryantSenior Vice President, HR and Administration · Since at least Nov 4, 2026
Hayley ParkerSenior Vice President, Global Regulatory Affairs & Quality · Since at least Nov 4, 2026
Hongling HanExecutive Director, Analytical Development and QC · Since at least Nov 4, 2026
Howard MayerNon-Executive Director · Since at least Jun 4, 2025
James McArthurPresident and Chief Executive Officer · Since at least May 5, 2022
Kasra KasraianChief Technical Officer · Since at least May 20, 2025
Lisa WymanDirector · Since at least Mar 27, 2025
Mary Beth DeLenaGeneral Counsel · Jan 15, 2024 – Mar 3, 2025 · Past
Melissa MichaelsExecutive Director, Head of Regulatory Affairs CMC · Since at least Nov 4, 2026
Michael ZhaoVice President, Head of Biometrics · Nov 4, 2026 – Nov 4, 2026 · Past
Michelle L MellionChief Medical Officer · May 5, 2022 – Jul 24, 2024 · Past
Mitch FinerNon-Executive Director · Since at least Nov 4, 2026
Niels SvenstrupSVP, Chem. Mfg & Controls · May 5, 2022 – May 17, 2024 · Past
Pallavi LonkarVice President, Head of Preclinical · Nov 4, 2026 – Nov 4, 2026 · Past
Paul StreckEVP, Head of R&D · Since at least Aug 19, 2024
Rod LozanoVice President, Information Technology · Nov 4, 2026 – Nov 4, 2026 · Past
Sarah VaccaExecutive Director, Clinical Operations · Since at least Nov 4, 2026
Sonia BracegirdleSee Remarks · May 5, 2022 – May 6, 2022 · Past

Open People

Log in to ask 6ix AI your own questions about PepGen Inc.